These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37947047)

  • 21. Polyamine-Targeting Gefitinib Prodrug and its Near-Infrared Fluorescent Theranostic Derivative for Monitoring Drug Delivery and Lung Cancer Therapy.
    Song X; Han X; Yu F; Zhang X; Chen L; Lv C
    Theranostics; 2018; 8(8):2217-2228. PubMed ID: 29721074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
    Wu W; O'Reilly MS; Langley RR; Tsan RZ; Baker CH; Bekele N; Tang XM; Onn A; Fidler IJ; Herbst RS
    Mol Cancer Ther; 2007 Oct; 6(10):2652-63. PubMed ID: 17913856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
    Oh HN; Lee MH; Kim E; Kwak AW; Seo JH; Yoon G; Cho SS; Choi JS; Lee SM; Seo KS; Chae JI; Shim JH
    Phytother Res; 2020 Feb; 34(2):388-400. PubMed ID: 31698509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of SLC7A11 gene downregulation on the gefitinib resistance of lung adenocarcinoma PC9/GR cells and its mechanism].
    Jia YL; Zhao Y; Zhen SM; Cheng ZS; Zheng BY; Liu YP; Liu LH
    Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):779-786. PubMed ID: 37805442
    [No Abstract]   [Full Text] [Related]  

  • 25. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
    Ihle NT; Paine-Murrieta G; Berggren MI; Baker A; Tate WR; Wipf P; Abraham RT; Kirkpatrick DL; Powis G
    Mol Cancer Ther; 2005 Sep; 4(9):1349-57. PubMed ID: 16170026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.
    Rogers SJ; Box C; Chambers P; Barbachano Y; Nutting CM; Rhŷs-Evans P; Workman P; Harrington KJ; Eccles SA
    J Pathol; 2009 May; 218(1):122-30. PubMed ID: 19197951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
    Xiao Z; Li M; Zhang X; Rong X; Xu H
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
    Engelman JA; Zejnullahu K; Gale CM; Lifshits E; Gonzales AJ; Shimamura T; Zhao F; Vincent PW; Naumov GN; Bradner JE; Althaus IW; Gandhi L; Shapiro GI; Nelson JM; Heymach JV; Meyerson M; Wong KK; Jänne PA
    Cancer Res; 2007 Dec; 67(24):11924-32. PubMed ID: 18089823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.
    Britain CM; Holdbrooks AT; Anderson JC; Willey CD; Bellis SL
    J Ovarian Res; 2018 Feb; 11(1):12. PubMed ID: 29402301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer.
    Averbuch SD
    Clin Lung Cancer; 2003 Sep; 5 Suppl 1():S5-S10. PubMed ID: 14641988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
    PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer.
    Bokobza SM; Jiang Y; Weber AM; Devery AM; Ryan AJ
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):947-54. PubMed ID: 24606853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37.
    Kim MS; Kim SH; Yang SH; Kim MS
    Cancer Res Treat; 2022 Apr; 54(2):445-457. PubMed ID: 34352998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.
    Kaneto N; Yokoyama S; Hayakawa Y; Kato S; Sakurai H; Saiki I
    Cancer Sci; 2014 Jul; 105(7):788-94. PubMed ID: 24750242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
    Raben D; Bianco C; Damiano V; Bianco R; Melisi D; Mignogna C; D'Armiento FP; Cionini L; Bianco AR; Tortora G; Ciardiello F; Bunn P
    Mol Cancer Ther; 2004 Aug; 3(8):977-83. PubMed ID: 15299080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
    Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
    Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Iwasa T; Yoshida T; Hatashita E; Yamada Y; Satoh T; Tamura K; Fukuoka M; Nakagawa K
    Mol Cancer Ther; 2008 Mar; 7(3):599-606. PubMed ID: 18347146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.